LSTA

0.86175.31%
JL

Joshua Lehrer-Graiwer

President & COO

Dr. Joshua Lehrer-Graiwer, M.Phil., M.D., FACC, also known as Josh, serves as President and Chief Operating Officer of Lisata Therapeutics, Inc. since September 17, 2026. He serves as the Chief Executive Officer, President and Director of Marea Therapeutics. He is Director of Fulcrum Therapeutics, Inc. from April 23, 2026. Dr. Lehrer-Graiwer served as the President, Chief Executive Officer and Director at Graphite Bio, Inc. since April 2020 until August 21, 2023. He served as Chief Medical Officer at Global Blood Therapeutics Inc. from October 1, 2019 to April 17, 2020. He served Senior Vice President of Clinical Development of Global Blood Therapeutics, Inc. from July 2017 to 2019. His track record advancing transformative therapies for patients with sickle cell disease, most notably his experience with the development and approval of Oxbryta®. He joined GBT in October 2013 as Medical Director. At GBT, he has overseen the clinical development organization and has led program strategy and execution for voxelotor (GBT440), bringing it through early-stage studies into a pivotal Phase 3 program in sickle cell disease. Prior to GBT, he led clinical development programs through proof of concept at Genentech in multiple indications and held key roles in business development and overseeing cardiovascular safety. He has served as adjunct faculty in the Division of Cardiology at Stanford School of Medicine. He holds an B.A. from Harvard College in Biochemistry and an M.Phil. In Biological Sciences from Cambridge University. He completed medical school and training in internal medicine at the University of California San Francisco (UCSF) and cardiology specialty training and postdoctoral research at Stanford University School of Medicine.

Positions